Immunorock

Immunorock is a biotechnology company focused on the discovery and development of next-generation precision immunotherapies for cancer. The company leverages its proprietary platform to engineer conditionally activated biologics, including bispecific T-cell engagers, that are designed to be selectively triggered within the tumor microenvironment. By minimizing off-tumor activity, Immunorock aims to overcome the safety limitations of current immunotherapies, such as cytokine release syndrome and systemic toxicity. Headquartered in Shanghai, the firm was founded by Dr. Li-Fan Lu, an expert in immunology and regulatory T-cell biology. Immunorock is currently advancing multiple programs through preclinical development with a focus on treating refractory solid tumors.